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Isolated limb perfusion with TNF  and melphalan in a rat 
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Isolated limb perfusion (ILP) with TNFa, IFNy and melphalan causes impressive tumour reduction in patients with 
irresectable soft tissue sarcomas with a high limb salvage rate. Since this therapy could be of value in patients with 
progressive osteosarcoma, we performed a study in an osteosarcoma tumour model in the rat. The ROS-! osteosareoma 
was implanted s.c. in the hind leg of WAG rats. Rats were divided in four groups: rats that underwent ILP with perfusate 
alone, TNFa alone, melphalan alone or their combination. Almost all rats, treated with a sham ILP or a perfusion with 
40 #g melphalan, showed progressive disease (PD) (616 and 516). After perfusion with 50 #g TNFct alone a varied response 
was observed: 216 PD, 216 no change (NC) and 216 a complete remission (CR). After combined perfusion: 3/6 rats had 
a partial remission and 316 a CR. The best and most consistent responses are obtained by combining TNF= and 
melphalan. The discrepancy with the in vitro sensitivity of ROS-I indicates that indirect effects are important in this 
tumour model. 
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Introduction 
Osteosarcoma is a rare tumour (1 to 2 cases per million 
each year) and occurs mainly in patients in the second 
decade of life. Despite its rarity, osteosarcoma h s attracted 
much attention, since pre- and post-operative chemotherapy 
increases survival rate considerably in patients with primary 
osteosarcoma. ~'-'Control of the primary tumour by pre- 
operative chemotherapy allows more conservative surgery ~
and the degree oftumour necrosis i an important prognostic 
factor. 4 Progressive disease in spite of chemotherapy is 
associated with a poor prognosis both with respect to local 
tumour control and survival. In most of these "lost cases' 
ablative surgery is needed with no hope of a cure. 
In these patients i olated limb perfusion (ILP) with TNF~, 
IFN7 and melphalan could be very beneficial, since this 
therapy often converts large tumours into necrotic, shrunken 
tumour remnants that can be resected at little functional 
cost of the extremity. This has been demonstrated for 
irresectable extremity soft tissue sarcomas (STS).S 7 
Rendering large tumours of the extremities resectable by 
loco-regional therapy has not only been described for STS 
but also for osteosarcoma: Vaglini et al. reported that 
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large osteosarcomas became resectable after hyperthermic- 
antiblastic perfusion in combination with intra-arterial nd 
intravenous chemotherapy in 11/18 of the patients,  ILP 
with TNFT, IFN7 and melphalan is less complex and avoids 
systemic administration f cytostatic agents and therefore 
needs to be evaluated in patients with irresectable 
osteosarcoma. 
In a previous tudy in rats we tbund that ILP with a 
combination of TNF~ and melphalan was effective against 
an aggressive soft tissue sarcoma in the Brown Norway 
ILP-rat model. '~ The aim of the present study is to investigate 
whether these effects can be found in the ROS-I 
osteosarcoma tumour model. In addition, we are interested 
in the role of direct cytotoxicity of the agents both alone 
and combined. The presence of indirect effects of both 
agents in this tumour model may provide a rationale to use 
this combination therapy in clinic, despite chemoresistance, 
which is principally based on direct cytotoxic effects only. 
Materials and methods 
Animals 
Male inbred WAG-Rij strain rats, weighing 250-300g 
obtained from Harlan-CPB (Austerlitz, The Netherlands) 
were used. The rats were fed a standard laboratory diet 
delivered by Hope Farms (Woerden, The Netherlands) and 
kept under standard laboratory conditions of light and 
accommodation. The experimental protocols adhered to the 
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rules laid down in the 'Dutch Animal Experimentation Act' 
(1977) and the 'Guidelines on the protection of Experimental 
Animals' published by the council of the EC (1986). The 
protocol was approved by the 'Committee on Animal 
Research' of the Erasmus University Rotterdam, The 
Netherlands. 
TLI71~OtO" 
The ROS-I osteosarcoma (transplantable to WAG/Rij rats) 
was used. This osteosarcoma originated spontaneously in 
the tibia of a rat. ~° Cells from this tumour were maintained 
in tissue culture and from these cultures new tumours were 
produced by inoculation in the flank. 
haemoglobin (Hb) content of the perfusate was 1.45 g/dl 
(0.9 mmol/I). Melphalan and TNF~ were added as boluses 
to the oxygenation reservoir. The roller pump (Watson 
Marlow, Falmouth, UK; type 505 U) recirculated the 
perfusate at a flow rate of 2.4 ml/min. A washout of 2 ml 
oxygenated Haemaccel was performed at the end of the 
perfusion. The collateral circulation via the internal iliac 
artery towards the leg is so extensive that it allows ligation 
of the femoral vessels without detrimental effects. Despite 
ligation of the femoral artery, back-flow from the femoral 
vein is seen in all rats immediately after release of the 
tourniquet. Moreover, in a previous tudy we measured the 
partial oxygen pressure (PaO_,) to be similar after ligation 
of the femoral vessels to that prior to perfusion, j~ 
Melphalan 
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, 
UK) was diluted in 10 ml diluent solvent. Further dilutions 
were made in 0.9"/,, NaCI to give a volume of 0.2 ml in the 
perfusion circuit. 
TNF~ 
Recombinant human TNF7 was provided by Boehringer 
(Ingelheim, Germany) with a specific activity of 5.8 × 10 7 U/ 
mg as determined in the murine L-M cell assay." Endotoxin 
levels were <1.25 EU/mg protein. 
Tttmoto" model 
Fragments of 3-5 mm were implanted in the right hind limb 
s.c. just above the ankle. Perfusion was performed at a 
tumour diameter of 15mm_+5mm at least 7 days after 
implantation. Tumour growth was recorded by calliper 
measurement. The mean of two perpendicular diameters 
was obtained. Tumour diameters were measured at least 
three times a week. 
Isolated Ihnb peT~fitsion 
We used a perfusion technique originally described by 
Benckhuijsen et al. ~'- with some modifications. ~3Briefly, 
Hypnorm (Janssen Pharmaceutica B.V., Tilburg, The 
Netherlands) was given as an anaesthetic and 50i.u. of 
heparin were injected i.v. To keep the rat's hind leg at a 
constant emperature of 38-39°C, a warm water mattress 
was applied around the leg. Temperature was monitored by 
a temperature probe (Ellab, Copenhagen, type DU-3) fixed 
at the convexity of the tumour. The femoral artery and vein 
were approached through an incision parallel to the inguinal 
ligament. Collaterals were temporarily occluded by the 
application of a tourniquet in the groin. The tourniquet 
was fixed at the inguinal ligament. The femoral artery and 
vein were cannulated with silastic tubing (0.30 mm ID, 0.64 
mm OD; 0.64 mm ID, 1.19 mm OD, respectively, Degania 
Silicone, Degania Bet, Israel). An isolation time of 30 min 
commenced when the tourniquet was tightened. An 
oxygenation reservoir and a roller pump were included in 
the circuit. The perfusion commenced with 5 ml Haemaccel 
(Behring Pharma, Amsterdam, The Netherlands) and the 
Tumour response studies 
The limbs of 24 rats were perfused. There were four 
experimental groups: sham perfusion (n---6), perfusion with 
50 ltg TNF:~ (n=6), 40/.tg melphalan perfusion (77=6) and 
pefusion with both 40 #g melphalan and 50Fg TNFz~ (n= 
6). The concentrations u ed are equivalent to those used in 
an efficacy study against he BN 175 fibrosarcoma in the 
BN rat." Since systemic administration of TNFz~ in clinic is 
limited by severe toxicity, it makes no sense to perform i.v. 
dose-effect studies in the rat. 
The classification for tumour response was: progresive 
disease (PD), increase of tumour diameter >25% within 10 
days; no change (NC), tumour diameter equal to diameter 
during perfusion _+ 25%; partial remission (PR), >25% 
decrease of tumour diameter; complete remission (CR), no 
palpable tumour. 
In vitro assessment of antitumour activiO' 
We determined the ht vitro sensitivity of ROS-I 
osteosarcoma for melphalan and TNF~. This cell line grows 
as a monolayer in Dulbecco's modified Eagle's medium 
supplemented with 5% fetal calf serum and glutamic acid 
(0.3mM), all obtained from Gibco (Paisley, UK), in a 
humidified atmosphere of CO,lair (5:95) at 37°C. We used 
the sulphorhodamine B (SRB) protein stain assay according 
to the method of Skehan et al.~4 Briefly, cells were isolated 
from cultures in the exponential growth phase by 
trypsinization, and counted, and plated in 96-well micro 
titre plates (Costar, Cambridge, MA). Each well contained 
100 FI 24 h after plating, 100¿d culture medium, or culture 
medium containing drug, was added to the wells. Seventy- 
two hours after drug addition cells were incubated with 
trichloroacetic a id (200 Fl/well) at 4°C for 1 h by means of 
protein precipitation and washed five times with tap water. 
The cells were stained for at least 15 min with 0.4% SRB 
dissolved in 1% acetic acid and subsequently washed 
thoroughly with 1% acetic acid to remove superfluous dye. 
After drying the plates, the bound protein stain was 
solubilized with 150 ltl 10 mM unbuffered TRIS. The optical 
density was read at 540 nm. All experiments were performed 
eight times. Tumour growth was calculated using the 
formula: tumour growth =(test well/control)× 100%. 
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Table 1. Tumour response of ROS-I osteosarcoma after ILP. 
Response Sham Melphalan TNF~ Melphalan + TNFa 
n=6 n=6 n=6 n=6 
Progressive disease 6 5 2 
No change I 2 
Partial remission 3 
Complete remission 2 3 
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Fig. 1. Growth curves of ROS-I osteosarcoma in the hind limb after sham (n=6, - -1 - - ) ,  melphalan 40pg (n=6, --[--I--), TNFc~ 50pg 
(n=6. - -0 - - )  and melphalan +TNF~ treatment 01=6, - -O-- ) .  The mean (+SEM) of the tumour diameters are depicted. Only statistically 
significant differences exist between the combined and sham group at day 3-15 after perfusion (SNK test: P<0.05). 
Statistical analysis 
Tumour diameters are given as means _+ SEM. Differences 
in results between the treatment groups were tested by 
Student Newman-Keul's (SNK) test, after one-way analysis 
of variance. 
Resu l ts  
ILP response studies 
In Table I the tumour responses of the different groups are 
summarized. Only in rats that were perfused with TNFc~ 
alone or with TNF~ in combination with melphalan, was 
tumour regression observed in 33% and 100% respectively. 
Sham perfusions or perfusions with melphalan alone did 
not result in tumour regression. In Fig. 1 the curves of the 
mean tumour diameters in the different groups are depicted. 
Only the group that underwent TNF~+melphalan 
perfusion showed a statistically significant (SNK test: 
P<0.05) difference to the group that received sham perfusion 
at 3-15 days after perfusion. 
The recurrence rate was 100%. Tumours reappeared 7-13 
days after perfusion. After recurrence tumours grew as fast 
as tumours in rats that had received sham perfusion. 
In vitro cytotoxicio, assay 
The dose/response curves of the ROS-I osteosarcoma cell 
line to TNF~ and melphalan are depicted in Fig. 2. ROS-I 
appeared to be relatively resistant o TNF~, as evidenced 
by 60"/0 growth at even very high concentrations (50 pg/ml) 
of TNF~. However, ROS-1 was sensitive to melphalan with 
an IC~ at 0.009 Itglml. 
In Fig. 3 the dose/response curves of ROS-I to melphalan 
is shown in the presence or absence of different 
concentrations of TNF~. The maximal growth of ROS-1, 
shown as a plateau at the lower concentrations melphalan, 
is reduced in the presence of TNFc~ in a concentration- 
dependent manner, which can be explained by addition of 
effects. The dose/response curves bend towards total growth 
inhibition at the same dose of melphalan independent of 
what concentration of TNF~ is used. Thus, these 
experiments could not reveal synergism in the direct tumour 
cytotoxic effects of both agents. 
Discuss ion  
The present study demonstrated that an experimental 
osteosarcoma responded in all rats treated with the 
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Fig. 2. Dose/response curves of ROS-I osteosarcoma to TNF~ ( - - , - - )  and melphalan (--O--) determined in the sulphorhodamine B 
assay. Cell number measured as absorbance in the colorimetric assay i  represented asa percentage of the control cell growth. 
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Fig. 3. Dose/response curve of ROS-I osteosarcoma to melphalan in the absence or presence ofvarious concentrations of TNF~,, determined 
in the sulphorhodamine B assay (--II--=melphalan (M) only; --1-1--= M +0.I iLg/ml TNF~; - -S - -=M + I ,ug/ml TNFa; - -O- -= 
M + I 0/tg/ml TNF~c) 
combination of TNF~ and melphalan in an ILP model. No 
statistically significant tumour esponse was noted in groups 
that were sham perfused or perfused with melphalan alone 
or TNFc~ alone. Perfusion with melphalan alone and sham 
perfusion was followed by progressive disease. After ILP 
with TNFu alone the response varied, but no consistent 
antitumour activity was observed. In spite of the absence 
of consistent antitumour effects of TNF~, the combination 
of TNF~ with melphalan showed clear synergistic 
antitumour activity resulting in a 100% response rate. These 
observations are in line with the synergy observed between 
TNFc~ and melphalan in the Brown Norway soft tissue 
sarcoma model. 9 Regarding the varied response to TNFa 
alone it should be kept in mind that anoxia in the tumour 
may be a critical determinant for its propensity to respond 
to TNFu alone? ~'mj~ and thus a variation in size or structure 
may explain why responses after TNF~ alone may vary. 
In contrast o the in vivo data the observations hi vitro 
show the relative resistance of ROS-I in culture to TNFu 
and its sensitivity to melphalan. Furthermore, no synergistic 
effects were observed in the in vitro experiments. Also, 
in previous studies the lack of correlation between direct 
tumour-cytotoxicity of TNFct and the in vivo tumour 
response has been shown/v:8 The opposite picture of the in 
vivo results to the in vitro results obtained in the present 
study makes it clear that indirect, host-mediated effects 
must be important in the tumour response of ROS-I, 
observed after ILP with TNFct+melphalan. 
The effect of TNFct on the neo-vasculature of the tumour 
has been the subject of many preclinical studiesfl -'~ The 
tumour esponse with evident haemorrhagic necrosis within 
24 h is characteristic for TNF~. -'~'24 Also in man vascular 
effects have been associated with the response on TNFc¢: in 
patients with soft issue sarcoma, treated with an ILP with 
TNFcq IFN7 and melphalan, the tumour response was 
associated with the angiographic disappearance of the 
tumour's neo-vasculature -'5 and with the histopathological 
findings of vascular occlusion and haemorrhagic necrosis. -'6'-'7 
In the present study, the tumour regression within 3 days 
is typical for the TNFc~ tumour response with a target role 
of the tumour's neo-vasculature. Also, the involvement of 
the immune system is considered to be important in the 
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TNFct tumour response and believed to be executed by the 
following mechanisms: (i) invasion of PMNs in the acute 
phase enhances the detrimental effects on the neo- 
vasculature.,7 .,9 and (ii) stimulation of inflammatory cells, 
e.g. lymphocytes, results in tumoricidal activity. The latter 
effect can result in a prolonged tumour control and is only 
described in immunogenic tumours? ° Since recurrences were 
found in all rats that showed tumour regression, we believe 
that the immune-mediated responses may not play an 
important role in our ILP model. 
The synergism between TNF~ and melphalan, observed 
in our tumour model, can be first explained by an 
enhancement by melphalan of the TNFct-induced vascular 
effects, since melphalan may well induce vascular damage, 
similar to that reported for the alkylating agent 
cyclophosphamide. 3~ A second underlying mechanism of the 
synergism could be an improved penetration of the cytostatic 
agent in the tumour by the TNF7 effects on the tumour's 
neo-vasculature. In previous studies vascular leakage and 
an enhanced accessibility of the therapeutical agent has 
been associated with a better tumour response. 3-''3~ Both 
mechanisms of synergism may well be relevant in the chemo- 
resistant osteosarcoma in man and therefore it seems 
justified that in a setting of ILP TNFct is combined with 
melphalan. 
To mimic the clinical situation ofadvanced osteosarcoma, 
we waited to treat tumours until they were relatively large. 
In the presence of an ineffective dose of melphalan, TNFct 
induced its typical quick tumour response, based on vascular 
effects. Thus, the concepts of targeting neo-vasculature also 
seems valid for experimental osteosarcoma. Since all large 
tumours are dependent on their neo-vasculature, irrespective 
of their histological type, we anticipate that ILP with TNFct 
and melphalan will be effective in all advanced 
osteosarcomas and thus may overcome the problem of 
chemoresistance. However, the early recurrences observed 
in all rats is a warning against too high an expectation of 
this combination therapy in the long term, and indicate that 
ILP with TNFct and melphalan should always be followed 
by dissection of the shrunken tumour remnants. 
Thus, in line with the experience in patients with locally 
advanced soft tissue sarcomas, ILP with TNFct and 
melphalan could be of great therapeutical benefit in patients 
with chemoresistant osteosarcoma to obtain local tumour 
control. 
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